Keytruda

News

BMS' subcutaneous Opdivo clears first phase 3 trial

Bristol-Myers Squibb is getting closer to offering a subcutaneous version of its cancer immunotherapy Opdivo to patients after it matched the current intravenous formulati

News

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

The combination of Bristol-Myers Squibb’s Opdivo and Yervoy cancer immunotherapies is on track for approval as a first-line therapy for patients with a particular form of

News

Keytruda breaks new ground in cervical cancer

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/

News

MSD, Moderna cancer vaccine aces melanoma study

MSD and Moderna’s individualised cancer vaccine mRNA-4157 has shown impressive efficacy in a phase 2b trial in skin cancer melanoma.

News

MSD, Moderna take mRNA jab into phase 3 for lung cancer

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non

News

BMS chases MSD/Seagen with first-line bladder cancer filing

The FDA has started a priority review of Bristol-Myers Squibb Opdivo in combination with cisplatin as a first-line therapy for advanced urothelial carcinoma (UC), setting

BMS' subcutaneous Opdivo clears first phase 3 trial

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

Keytruda breaks new ground in cervical cancer

MSD, Moderna cancer vaccine aces melanoma study

MSD, Moderna take mRNA jab into phase 3 for lung cancer

BMS chases MSD/Seagen with first-line bladder cancer filing

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Keytruda

Editor's Picks